Screener
ImmunityBio, Inc. IBRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $205,194 | $88,334 |
| Marketable securities | 175,685 | 154,484 |
| Accounts receivable, net | 43,271 | 42,571 |
| Inventories | 547 | 910 |
| Due from related parties | 3 | 46 |
| Prepaid expenses and other current assets | 26,182 | 27,761 |
| Prepaid expenses – related parties | 2,071 | 769 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s accounts receivable?
- ImmunityBio, Inc. (IBRX) reported accounts receivable of $43.27M in Q1 2026.
- How has ImmunityBio, Inc.'s accounts receivable changed year-over-year?
- ImmunityBio, Inc.'s accounts receivable increased by 154.1% year-over-year, from $17.03M to $43.27M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about ImmunityBio, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude